|
Munich, August, 26th 2011
Phase III Distributive Shock Trial (“PHOENIX trial”) Terminated for
Futility
The PHOENIX trial is a European, placebocontrolled, Phase III study treating
patients in catecholamine-resistant, distributive shock with the Nitric Oxide (NO) scavenger PHP /
Hemoximer. The study was launched by Curacyte AG in Austria, Belgium, Germany, Spain, The
Netherlands and in the United Kingdom in 2009.
|
|
